Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Asian markets in the red again 
(Thu, 7 Aug 09:30 am) 
All major Asian stock markets have opened the day in the red with stock markets in China (down 0.6%) and Hong Kong (down 0.5 %) leading the pack of losers. The Indian share markets have also opened the day on a negative note. The sectoral indices are trading mixed with the information technology index leading the losses. However, the capital goods index is trading firm.

The Sensex today is down by around 26 points (0.1%), while the NSE-Nifty is down by about 6 points (0.1%). However, mid and small cap stocks are trading in the green with the BSE Mid Cap and BSE Small Cap indices up by around 0.3% and 0.4% respectively. The rupee is currently trading at Rs 61.29 to the US dollar.

Public Sector Bank stocks have opened the day on a mixed note with Union Bank of India and Allahabad Bank leading the gains. However, IDBI Bank and Indian Overseas Bank are trading weak. Public sector lender IDBI Bank has announced its results for the quarter ended June 2014. During the quarter, the bank reported flat growth at the topline level with interest earned standing at Rs 67,329.8 m. Other income declined by 30.3% YoY to Rs 4,997.5 m. Owing to higher interest expended, operating income before provisions and contingencies dropped by 29.5% YoY to Rs 9,282.6 m. At the bottomline level, net profit plunged by 65.4% YoY to Rs 1,061.7 m. Net profit margin contracted from 4.6% in 1QFY14 to 1.6% in 1QFY15.

Indian Pharma stocks have mainly opened the day on a firm note with Indoco Remedies and Glenmark Pharma leading the gains. As per the financial daily, Mumbai-based pharma major Lupin has signed a marketing pact with South Korea's LG Life Sciences to launch its anti-diabetes drug in India. According to the agreement, Lupin will launch and will be responsible for the marketing and sales of LG Life Sciences' Insulin Glargine, a novel insulin analogue, under the brand name BasugineTM. It must be noted that Insulin Glargine is indicated for the treatment of adult patients with type 1 diabetes mellitus or in type 2 diabetes mellitus. This deal will help Lupin further strengthen its diabetes portfolio. As per IMS MAT data reported in the daily, the overall diabetes market size within the Indian pharmaceutical Market (IPM) stands at Rs 60.32 bn and is growing at 18% year-on-year.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Asian markets in the red again". Click here!



Apr 25, 2017 02:00 PM